Vetter's €1.5 billion investment focuses on expanding commercial and clinical production, with a new plant in Saarlouis, Germany, creating up to 2,000 jobs. The US expansion prioritizes clinical ...
Repertoire Immune Medicines partners with Eli Lilly to develop tolerizing therapies for autoimmune diseases, receiving $85 ...
Ultimately, the interview underscores a critical transition period for the industry. While tariffs present a unique hurdle ...
Cellares. Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the ...
Government shutdowns lead to decreased predictability, causing delays in new submissions and manufacturing changes. Key risk ...
Mirum Pharmaceuticals acquires Bluejay Therapeutics, focusing on brelovitug for chronic hepatitis delta virus (HDV), a severe ...
February 11 is the International Day of Women and Girls in Science (1). This day focuses on the gender gap in science, ...
Arexvy, GSK's RSV vaccine, is now approved for all adults 18+ in the EU, addressing a significant public health concern. RSV ...
Halo Pharma becomes a standalone drug product CDMO after the sale of Noramco’s API assets, adding sterile services by H2 2026 ...
Rare disease clinical trials are smaller and often use surrogate endpoints, reducing costs but posing unique operational ...
PharmTech is rebranding to strengthen its commitment to scientists, innovators, and executives in the pharmaceutical industry ...
Eli Lilly will invest $3.5 billion in a Pennsylvania facility for injectable weight-loss medicines, creating 850 new jobs and starting by 2031.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results